The use of molecules to inhibit elements of the NF-κB signaling pathway has also been suggested as a therapeutic option for neurological disorders such as [56] multiple sclerosis, Parkinson’s disease [57], Alzheimer’s disease [58], and spontaneous intracerebral hemorrhage [38]. This evidence concerns the gene NFKB1 and early-onset autosomal dominant Alzheimer disease.